stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Current ratio
Viridian Therapeutics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 14.5×, up 1.8× from fiscal 2025 (12.6×). Over the past ten years it has ranged from 2.9× (fiscal 2019) to 18.3× (fiscal 2023); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 12.6× | (18.00%) |
| FY2024 | 15.4× | (15.55%) |
| FY2023 | 18.3× | 41.27% |
| FY2022 | 12.9× | (11.92%) |
| FY2021 | 14.7× | 20.89% |
| FY2020 | 12.1× | 315.66% |
| FY2019 | 2.9× | (69.91%) |
| FY2018 | 9.7× | (27.05%) |
| FY2017 | 13.3× | 283.79% |
| FY2016 | 3.5× | (27.06%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 14.5× | (14.67%) |
| Jun 2026 | 16.9× | 11.89% |
| Mar 2026 | 15.1× | 19.76% |
| Dec 2025 | 12.6× | 12.12% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 64.1× |
| VRDN Viridian Therapeutics, Inc. | 14.5× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| DNLI Denali Therapeutics Inc. compare | 6.2× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement